FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030483640> ?p ?o ?g. }

• W3030483640 abstract "Delayed graft function, the requirement for dialysis due to poor kidney function post-transplant, is a frequent complication of deceased donor kidney transplantation and is associated with inferior outcomes and higher costs. Intravenous fluids given during and after transplantation may affect the risk of poor kidney function after transplant. The most commonly used fluid, isotonic sodium chloride (0.9% saline), contains a high chloride concentration, which may be associated with acute kidney injury, and could increase the risk of delayed graft function. Whether using a balanced, low-chloride fluid instead of 0.9% saline is safe and improves kidney function after deceased donor kidney transplantation is unknown.BEST-Fluids is an investigator-initiated, pragmatic, registry-based, multi-center, double-blind, randomized controlled trial. The primary objective is to compare the effect of intravenous Plasma-Lyte 148 (Plasmalyte), a balanced, low-chloride solution, with the effect of 0.9% saline on the incidence of delayed graft function in deceased donor kidney transplant recipients. From January 2018 onwards, 800 participants admitted for deceased donor kidney transplantation will be recruited over 3 years in Australia and New Zealand. Participants are randomized 1:1 to either intravenous Plasmalyte or 0.9% saline peri-operatively and until 48 h post-transplant, or until fluid is no longer required; whichever comes first. Follow up is for 1 year. The primary outcome is the incidence of delayed graft function, defined as dialysis in the first 7 days post-transplant. Secondary outcomes include early kidney transplant function (composite of dialysis duration and rate of improvement in graft function when dialysis is not required), hyperkalemia, mortality, graft survival, graft function, quality of life, healthcare resource use, and cost-effectiveness. Participants are enrolled, randomized, and followed up using the Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry.If using Plasmalyte instead of 0.9% saline is effective at reducing delayed graft function and improves other clinical outcomes in deceased donor kidney transplantation, this simple, inexpensive change to using a balanced low-chloride intravenous fluid at the time of transplantation could be easily implemented in the vast majority of transplant settings worldwide.Australian New Zealand Clinical Trials Registry: ACTRN12617000358347. Registered on 8 March 2017. ClinicalTrials.gov: NCT03829488. Registered on 4 February 2019." @default.
• W3030483640 created "2020-06-05" @default.
• W3030483640 creator A5001559641 @default.
• W3030483640 creator A5010978049 @default.
• W3030483640 creator A5017481619 @default.
• W3030483640 creator A5020609807 @default.
• W3030483640 creator A5038007882 @default.
• W3030483640 creator A5039286361 @default.
• W3030483640 creator A5041538148 @default.
• W3030483640 creator A5043394711 @default.
• W3030483640 creator A5045764823 @default.
• W3030483640 creator A5054634839 @default.
• W3030483640 creator A5056742179 @default.
• W3030483640 creator A5060721703 @default.
• W3030483640 creator A5073772726 @default.
• W3030483640 creator A5077107645 @default.
• W3030483640 creator A5080872947 @default.
• W3030483640 creator A5086260890 @default.
• W3030483640 creator A5087647894 @default.
• W3030483640 date "2020-05-25" @default.
• W3030483640 modified "2023-10-07" @default.
• W3030483640 title "Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9% saline on delayed graft function in deceased donor kidney transplantation" @default.
• W3030483640 cites W1518077170 @default.
• W3030483640 cites W1561293316 @default.
• W3030483640 cites W1649543050 @default.
• W3030483640 cites W1853219683 @default.
• W3030483640 cites W1931781407 @default.
• W3030483640 cites W1966186276 @default.
• W3030483640 cites W1972449270 @default.
• W3030483640 cites W1993674429 @default.
• W3030483640 cites W1995721474 @default.
• W3030483640 cites W2002770567 @default.
• W3030483640 cites W2008702734 @default.
• W3030483640 cites W2014698393 @default.
• W3030483640 cites W2024754526 @default.
• W3030483640 cites W2035170959 @default.
• W3030483640 cites W2064428058 @default.
• W3030483640 cites W2074769157 @default.
• W3030483640 cites W2082340087 @default.
• W3030483640 cites W2093274439 @default.
• W3030483640 cites W2108298583 @default.
• W3030483640 cites W2109968192 @default.
• W3030483640 cites W2121185244 @default.
• W3030483640 cites W2122855609 @default.
• W3030483640 cites W2123430849 @default.
• W3030483640 cites W2124105308 @default.
• W3030483640 cites W2135146312 @default.
• W3030483640 cites W2139645437 @default.
• W3030483640 cites W2142057837 @default.
• W3030483640 cites W2144106531 @default.
• W3030483640 cites W2155965977 @default.
• W3030483640 cites W2165995565 @default.
• W3030483640 cites W2312346632 @default.
• W3030483640 cites W2315309736 @default.
• W3030483640 cites W2509590939 @default.
• W3030483640 cites W2539440081 @default.
• W3030483640 cites W2547121147 @default.
• W3030483640 cites W2600542038 @default.
• W3030483640 cites W2733371386 @default.
• W3030483640 cites W2752161589 @default.
• W3030483640 cites W2790158735 @default.
• W3030483640 cites W2803000548 @default.
• W3030483640 cites W2911060459 @default.
• W3030483640 cites W2948568340 @default.
• W3030483640 cites W3000769209 @default.
• W3030483640 cites W4241014756 @default.
• W3030483640 doi "https://doi.org/10.1186/s13063-020-04359-2" @default.
• W3030483640 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7249430" @default.
• W3030483640 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32450917" @default.
• W3030483640 hasPublicationYear "2020" @default.
• W3030483640 type Work @default.
• W3030483640 sameAs 3030483640 @default.
• W3030483640 citedByCount "16" @default.
• W3030483640 countsByYear W30304836402021 @default.
• W3030483640 countsByYear W30304836402022 @default.
• W3030483640 countsByYear W30304836402023 @default.
• W3030483640 crossrefType "journal-article" @default.
• W3030483640 hasAuthorship W3030483640A5001559641 @default.
• W3030483640 hasAuthorship W3030483640A5010978049 @default.
• W3030483640 hasAuthorship W3030483640A5017481619 @default.
• W3030483640 hasAuthorship W3030483640A5020609807 @default.
• W3030483640 hasAuthorship W3030483640A5038007882 @default.
• W3030483640 hasAuthorship W3030483640A5039286361 @default.
• W3030483640 hasAuthorship W3030483640A5041538148 @default.
• W3030483640 hasAuthorship W3030483640A5043394711 @default.
• W3030483640 hasAuthorship W3030483640A5045764823 @default.
• W3030483640 hasAuthorship W3030483640A5054634839 @default.
• W3030483640 hasAuthorship W3030483640A5056742179 @default.
• W3030483640 hasAuthorship W3030483640A5060721703 @default.
• W3030483640 hasAuthorship W3030483640A5073772726 @default.
• W3030483640 hasAuthorship W3030483640A5077107645 @default.
• W3030483640 hasAuthorship W3030483640A5080872947 @default.
• W3030483640 hasAuthorship W3030483640A5086260890 @default.
• W3030483640 hasAuthorship W3030483640A5087647894 @default.
• W3030483640 hasBestOaLocation W30304836401 @default.
• W3030483640 hasConcept C120665830 @default.
• W3030483640 hasConcept C121332964 @default.
• W3030483640 hasConcept C126322002 @default.
• W3030483640 hasConcept C141071460 @default.
• W3030483640 hasConcept C159641895 @default.

• next